Study Watch with Irregular Pulse Monitor (Home), Study Watch with Irregular Pulse Monitor

The Study Watch with Irregular Pulse Monitor is a prescription-only wearable device designed for adult patients with or at risk of atrial fibrillation, enabling them to record single-channel ECGs and monitor for irregular pulses using photoplethysmography (PPG). Its machine learning algorithm, trained on ECG and PPG data, analyzes PPG signals to detect potential atrial fibrillation, prompting ECG capture, with data then securely transferred for healthcare professional review and potential further analysis via interoperable systems.

The Study Watch with Irregular Pulse Monitor is a prescription-based wearable system intended for adult patients (22 years and older) diagnosed with or susceptible to atrial fibrillation (AF). Its primary purpose is to enable patients to monitor and record their heart rhythms through single-channel electrocardiogram (ECG) measurements and continuous irregular pulse detection using photoplethysmography (PPG). The system comprises a watch with two sensing electrodes for ECG capture and a PPG sensor, a charging cradle, a data transfer application (Study Hub or Watch App), and a web portal for healthcare professionals (HCPs). Patients can initiate a 45-second ECG recording on-demand or when prompted by an irregular pulse notification. These ECG recordings are securely transferred to a cloud server for HCP review via the web portal, which displays time-stamped waveforms but does not include analysis features; data may also be sent to interoperable systems like iRhythm's ZEUS System for further analysis. The device employs a machine learning algorithm for its Irregular Pulse Monitoring feature, which analyzes wrist-based PPG data. This algorithm operates continuously, assessing 15-minute segments of PPG data every 15 minutes to identify irregular rhythms suggestive of AF. It was trained using extensive ECG data from iRhythm Technologies’ Zio devices and tuned with PPG data from similar devices. Clinical validation for home use (Study NCT04546763) compared Study Watch PPG data against contemporaneous ECG data from a reference Zio XT Patch, demonstrating a per-interval sensitivity of 96.1% and specificity of 98.1% for irregular pulse detection in an ambulatory setting. Key updates from its predicate include expanded indications for home use and improved performance metrics for irregular pulse detection.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the 45-second ECG recording duration compare to the predicate's 60-second duration in terms of diagnostic yield for atrial fibrillation, and what was the rationale for this change?; What specific machine learning techniques were employed in the development of the Irregular Pulse Monitoring Algorithm, and how was the dataset (ECG from Zio devices, PPG from similar devices) balanced and preprocessed during algorithm training?; Given that the patient does not have direct access to the collected ECG waveform on the watch, what mechanisms are in place to ensure patient understanding and compliance with ECG capture recommendations, particularly following an irregular pulse notification?; What are the specific data security and privacy measures implemented for the transfer and storage of sensitive ECG and PPG data, especially considering its transmission to Verily's cloud server and its interoperability with third-party systems like the ZEUS System?; How does the performance of the PPG-based irregular pulse detection (sensitivity 96.1%, specificity 98.1% in home use) vary across different patient subgroups, such as those defined by age, gender, comorbidities, or skin tone, within the validated population?